Beijing Pharmaceutical Group To Accelerate Business Integration
This article was originally published in PharmAsia News
Beijing Pharmaceutical Group's commercial business is contributed by its five entities across China: Worldbest Pharmaceutical in Anhui, Beijing Pharmaceutical in Beijing, Double-crane Pharmaceutical in Kunshan, Xin-xibei Double-crane Medicine in Xi'an and Double-crane Medicine in Changsha. The group revealed that it plans to integrate its pharmaceutical business to maintain its market share in North China and achieve market penetration in areas such as Anhui, Hunan and Shaanxi. Analysts observe that China's pharmaceutical giants like Nanjing Medical Company, Guangzhou Pharmaceutical and Shanghai Pharmaceutical frequently formulate strategies to grab distribution channels and resources; their activities may have spurred Beijing Pharmaceutical Group's latest direction. (Click here for more - Chinese Language)
You may also be interested in...
Guardant’s CEO anticipates accelerated adoption and reimbursement of its FDA-approved liquid biopsy assay and more biopharma partnerships.
Public Company Edition: The German mRNA-focused company could raise up to $245m based on its proposed price range, but investor interest could drive the offering’s total higher. Also, Perceptive launches another SPAC, Regeneron sells $2bn in debt and Biohaven secures up to $950m.
Agency commissioner appeals to AMA audience to communicate message that FDA review decisions are based on good science.